| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | President | Chief Operating Officer
3 companies
Daniel Virnich is Chief Executive Officer at TOIIW and has filed Form 4s across 3 companies. Daniel Virnich's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $22.1M at current prices.
The biggest single holding is STLN (~$14.8M) as Chief Executive Officer.
Daniel Virnich has 20 Form 4 filings on record from November 2021 to May 2026, across 3 companies: Chief Executive Officer at Starling Oncology (STLN), 2026; Chief Executive Officer at The Oncology Institute (TOIIW), 2026; Chief Executive Officer at Oncology Institute (TOI), 2021–2025.
The 33 reported transactions were 10 stock awards, 8 dispositions back to the company, 6 option or other derivative awards and 5 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $24K and no sales.
The only open-market purchase was 22,640 shares of TOI at an average $1.04 on March 26, 2025, about $24K. Twelve months later TOI was up 156%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2025 | TOI Oncology Institute, Inc. | Chief Executive Officer | Buy | 22,640 | $1.04 | $23,584.09 | +3.2% | +94.2% | +156.2% |